By David Bornstein
Earlier this week, I reported on the Myelin Repair Foundation (M.R.F.), an organization that is working to develop a novel treatment for multiple sclerosis, a degenerative disease that currently has no cure. Over the past four decades, despite extraordinary advances in bioscience, cures for many chronic diseases have remained elusive. As Norman from New York City (17) noted, the survival rates for many cancers have not changed much since the launch of the nation’s war on cancer during the Nixon administration: “The death rate has only declined by 3.3 percent or less in colon cancer, breast cancer, prostate cancer, and leukemia.” In response, groups like the M.R.F. have begun exploring new models to accelerate research and hasten the development of new treatments for disease.